Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew Lunning

Showing results (31-40 of 59) with videos related to

Pageof 6
Sort By:
Future Oncology (London, England)|March 28, 2024
Plain language summary of the TRANSFORM study primary analysis results: liso-cell as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimenJeremy S Abramson, Scott R Solomon, Jon Arnason, et al.
Leukemia & Lymphoma|April 5, 2018
Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myelomaAjai Chari, Sarah Larson, Beata Holkova, et al.
Blood Advances|October 1, 2020
T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphomaPaola Ghione, Promie Faruque, Neha Mehta-Shah, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2023
Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design StudyMichael Wang, Tanya Siddiqi, Leo I Gordon, et al.
Lancet (London, England)|June 19, 2022
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trialManali Kamdar, Scott R Solomon, Jon Arnason, et al.
Bone Marrow Transplantation|August 11, 2022
Split dose ATG strategy prevents grade III-IV acute GVHD and is associated with immune surrogates of GVLZaid Al-Kadhimi, Samuel Pirruccello, Zartash Gul, et al.
Transplantation and Cellular Therapy|November 14, 2025
CRS or ICANS Are Rare Beyond 2 Weeks After Lisocabtagene Maraleucel Infusion: Data From Clinical Trials and the Real-World SettingBradley D Hunter, Matthew Lunning, Mazyar Shadman, et al.
JCO Global Oncology|October 29, 2025
Advanced Classical Hodgkin Lymphoma Management in East and Southeast Asia: Real-World Challenges and Aspirations of the Asian Lymphoma Study GroupJason Yongsheng Chan, Ayumi Fujimoto, Gin Gin Gan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 7, 2025
Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM StudyManali Kamdar, Scott R Solomon, Jon Arnason, et al.
Haematologica|June 11, 2026
Outcomes in early stage peripheral T-cell lymphoma by stage, histology, and treatment patternsRobert Stuver, Zachary R Moore, Stefan K Barta, et al.
Pageof 6

Showing results (31-40 of 59) with videos related to

Sort By:
Pageof 6
Future Oncology (London, England)|March 28, 2024
Plain language summary of the TRANSFORM study primary analysis results: liso-cell as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimenJeremy S Abramson, Scott R Solomon, Jon Arnason, et al.
Leukemia & Lymphoma|April 5, 2018
Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myelomaAjai Chari, Sarah Larson, Beata Holkova, et al.
Blood Advances|October 1, 2020
T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphomaPaola Ghione, Promie Faruque, Neha Mehta-Shah, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2023
Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design StudyMichael Wang, Tanya Siddiqi, Leo I Gordon, et al.
Lancet (London, England)|June 19, 2022
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trialManali Kamdar, Scott R Solomon, Jon Arnason, et al.
Bone Marrow Transplantation|August 11, 2022
Split dose ATG strategy prevents grade III-IV acute GVHD and is associated with immune surrogates of GVLZaid Al-Kadhimi, Samuel Pirruccello, Zartash Gul, et al.
Transplantation and Cellular Therapy|November 14, 2025
CRS or ICANS Are Rare Beyond 2 Weeks After Lisocabtagene Maraleucel Infusion: Data From Clinical Trials and the Real-World SettingBradley D Hunter, Matthew Lunning, Mazyar Shadman, et al.
JCO Global Oncology|October 29, 2025
Advanced Classical Hodgkin Lymphoma Management in East and Southeast Asia: Real-World Challenges and Aspirations of the Asian Lymphoma Study GroupJason Yongsheng Chan, Ayumi Fujimoto, Gin Gin Gan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 7, 2025
Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM StudyManali Kamdar, Scott R Solomon, Jon Arnason, et al.
Haematologica|June 11, 2026
Outcomes in early stage peripheral T-cell lymphoma by stage, histology, and treatment patternsRobert Stuver, Zachary R Moore, Stefan K Barta, et al.
Pageof 6